United States: Hatch-Waxman Infringement Claims And FDA Citizen Petition May Violate Antitrust Laws

In Tyco Healthcare Group LP v. Mutual Pharmaceutical Co., No. 13-1386 (Fed. Cir. Aug. 6, 2014), the Federal Circuit affirmed-in-part and vacated-in-part the district court's SJ decision that Hatch-Waxman infringement claims and a citizen petition filed with the FDA did not violate the antitrust laws.

Tyco Healthcare Group LP and Mallinckrodt, Inc. (collectively "Tyco") own several patents directed to temazepam (brand name Restoril), a drug used to treat insomnia.  The patents all claim 7.5 mg formulations of temazepam having a specific surface area between 0.65 and 1.1 square meters per gram (m2/g).  Although the claims do not recite any measurement technique, the patent specifications state that surface-area measurements are made essentially in accordance with a known gas-adsorption technique, B.E.T. testing, which involves an outgassing step generally performed at an elevated temperature.  Tyco used an outgassing temperature of 105°C in its B.E.T. testing.

Mutual Pharmaceutical Company, Inc. and United Research Laboratories, Inc. (collectively "Mutual") filed an ANDA seeking FDA approval of a generic 7.5 mg version of temazepam.  Mutual's ANDA represented that the specific surface area of its proposed ANDA product would be not less than 2.2 m2/g and thus made a Paragraph IV certification of noninfringement.  Mutual used an outgassing temperature of 40°C in its B.E.T. testing. 

Tyco sued Mutual, alleging infringement under 35 U.S.C. § 271(e)(2)(A).  Mutual raised antitrust counterclaims, which the district court stayed pending resolution of Tyco's infringement claim.  The district court first entered judgment of noninfringement.  The next day—one week before the end of the statutory thirty-month stay of Mutual's ANDA approval—Tyco filed a citizen petition with the FDA.  The citizen petition urged the FDA to change the parameters of evaluating the bioequivalence of generic temazepam.  The FDA nevertheless approved Mutual's ANDA and, five months later, denied the citizen petition, finding "no basis" for adopting Tyco's proposed bioequivalence criteria.  Slip op. at 5.  The district court later granted SJ to Mutual on invalidity, which the Federal Circuit affirmed.  Afterwards, the district court granted SJ to Tyco on all of Mutual's antitrust counterclaims, including that Tyco's infringement claim constituted sham litigation, that Tyco's citizen petition was a sham, and that Tyco's action was the product of fraud within the meaning of Walker Process Equipment, Inc. v. Food Machinery & Chemical Corp., 382 U.S. 172 (1965).  Mutual appealed.

"[I]t is not unreasonable for a patent owner to allege infringement under section 271(e)(2)(A) if the patent owner has evidence that the as-marketed commercial ANDA product will infringe, even though the hypothetical product specified in the ANDA could not infringe."  Slip op. at 10.

On appeal, the Federal Circuit rejected Mutual's first argument that a genuine dispute existed as to whether Tyco's infringement suit was objectively baseless and, thus, fell within the sham-litigation exception to Noerr-Pennington antitrust immunity.  Mutual argued that because its ANDA recited a specific surface area falling outside the claimed range, its proposed generic could not infringe.  The Court disagreed, explaining that the infringement inquiry in an ANDA case focuses on what is likely to be sold following FDA approval and is not limited to the ANDA itself. 

Nonetheless, the Court vacated the district court's SJ decision regarding sham litigation and remanded.  According to the Court, under Tyco's infringement theory, Mutual's use of 40°C as the outgassing temperature was inappropriate and that 105°C—the temperature at which Tyco tested Restoril—should have been used instead.  While the parties did not dispute that Mutual's generic temazepam fell within the infringing range at an outgassing temperature of 105°C, the Court noted that there was also evidence that using 105°C physically altered the temazepam, inappropriately decreasing the specific surface area, and that, barring physical alterations, higher outgassing temperatures would potentially increase, not decrease, the surface area.  The Court therefore concluded that, because Tyco's infringement theory would make it more likely that Mutual's commercial product would measure outside of the infringement range, further inquiry was required as to whether Tyco's factual theory of infringement was objectively baseless.

In contrast, the Federal Circuit affirmed SJ for Tyco on the invalidity portion of Mutual's sham-litigation counterclaim.  According to Mutual, Tyco lacked a reasonable prospect of success in defending the nonobviousness of its patents because the only novel claim element was the 7.5 mg dose, which fell within a range disclosed in the prior art.  The Court explained that although this scenario shifted the burden of production to the patent holder, it did not remove the burden of proof from the patent challenger.  And, according to the Court, not only did Tyco offer evidence to meet its burden of production, which Mutual ignored, but also Tyco's "teaching away" argument was not objectively baseless.

Next, the Federal Circuit vacated the district court's SJ decision that Tyco's citizen petition was not a sham.  First, following the precedent from other circuits, the Court held that the sham exception to Noerr-Pennington immunity was not limited to litigation, but also applied to administrative petitions, including FDA citizen petitions.  Second, the Court held that disputed factual issues precluded SJ regarding whether the citizen petition was objectively baseless.  The Court noted that particularly probative of whether the citizen petition was reasonable was the FDA's denial, which indicated that the FDA viewed the petition as wholly without merit.  The Court also noted that Mutual's expert concluded that Tyco lacked a scientific basis to conclude that Mutual's product would not be bioequivalent.  Third, regarding the subjective element of the test, the Court held that the timing of Tyco's citizen petition and an internal e-mail indicating that a bioequivalent temazepam formulation could be made with a different specific surface area together could support a finding that the petition was an attempt to interfere directly with a competitor's business relationships.  The Court noted, however, that it remained an open question whether the filing of the citizen petition caused any antitrust injury to Mutual via a delay in its ANDA approval and that SJ for Tyco may still be appropriate on this basis.

Finally, the Court affirmed SJ on Mutual's claim that Tyco's predecessor in interest had fraudulently obtained the asserted patents from the PTO by omitting material information during prosecution and that Tyco had at least constructive knowledge of the fraud.  The Court held that there was insufficient evidence that Tyco knew of any fraud, concluding instead that Mutual's evidence, at most, supported the inference that Tyco knew of prior art that could impact the validity or enforceability of the patents.

Accordingly, the Court affirmed SJ for Tyco on Mutual's antitrust counterclaims predicated on sham litigation regarding validity and on fraud, and vacated and remanded those predicated on sham litigation regarding Tyco's infringement claim and the citizen petition.

Dissenting, Judge Newman stated that the panel majority had created several new grounds of antitrust liability.  In her view, litigation to enforce a presumptively valid patent following a Paragraph IV certification—a technical act of infringement under 35 U.S.C. § 271(e)—cannot be objectively baseless because the certification constitutes probable cause to initiate suit.  In addition, she stated that Tyco had the constitutional right to communicate with the FDA concerning public information on matters within the agency's authority and responsibility without incurring antitrust liability.  Thus, according to Judge Newman, "[t]he panel majority improperly inserts antitrust issues into the issues of infringement, validity, and communication to the government, contravening precedent and the Constitution."  Newman Dissent at 3-4.

Judges:  Newman (dissenting), Bryson (author), Moore

[Appealed from D.N.J., Judge Chesler]

This article previously appeared in Last Month at the Federal Circuit, September 2014.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
27 Nov 2017, Seminar, London, UK

Finnegan partner Anthony Tridico will present “U.S. Patent Case Law Update” at the Chartered Institute of Patent Attorneys’ annual Patent Case Law Review.

28 Nov 2017, Seminar, Milan, Italy

Finnegan partner John Paul will present “Internet of Things: Patent Liability, Enforcement and Licensing” and will join the Mock WIPO Mediation at International Technology Transfer—Licensing and ADR, co-hosted by Licensing Executives Society and World Intellectual Property Organization.

29 Nov 2017, Seminar, Tel Aviv, Israel

Finnegan is a platinum sponsor IVC Research Center’s start-up forum, “The Most Promising Start Ups for 2017 – A Synergy of Big Data, Artificial Intelligence, Machine Vision and IoT.”

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.